Marshall Wace’s Intersect ENT, Inc XENT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-121,032
| Closed | -$3.39M | – | 4071 |
|
|
2022
Q1 | $3.39M | Buy |
121,032
+55,474
| +85% | +$1.52M | 0.01% | 1700 |
|
|
2021
Q4 | $1.79M | Buy |
+65,558
| New | +$1.78M | ﹤0.01% | 2111 |
|
|
2021
Q3 | – | Sell |
-30,076
| Closed | -$514K | – | 3609 |
|
|
2021
Q2 | $514K | Buy |
+30,076
| New | +$563K | ﹤0.01% | 2110 |
|
|
2020
Q4 | – | Sell |
-15,577
| Closed | -$254K | – | 2319 |
|
|
2020
Q3 | $254K | Buy |
+15,577
| New | +$282K | ﹤0.01% | 1406 |
|
|
2019
Q1 | – | Sell |
-84,886
| Closed | -$2.39M | – | 2164 |
|
|
2018
Q4 | $2.39M | Buy |
84,886
+5,587
| +7% | +$164K | 0.02% | 686 |
|
|
2018
Q3 | $2.28M | Buy |
+79,299
| New | +$2.38M | 0.02% | 650 |
|
|
2017
Q2 | – | Sell |
-301,698
| Closed | -$5.13M | – | 403 |
|
|
2017
Q1 | $5.13M | Buy |
+301,698
| New | +$4.23M | 0.25% | 89 |
|
|
2016
Q2 | – | Sell |
-19,400
| Closed | -$369K | – | 1232 |
|
|
2016
Q1 | $369K | Buy |
+19,400
| New | +$351K | ﹤0.01% | 899 |
|
Marshall Wace's XENT Position: Q2 2022 in Review
Marshall Wace sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 121,032 shares — an estimated $3.39M sold.
Marshall Wace first reported a position in XENT in Q1 2016 and held it in 8 quarters. The position peaked at $5.13M in Q1 2017. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.
- Marshall Wace reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
- Marshall Wace sold 121,032 Intersect ENT, Inc shares in Q2 2022, an estimated $3.39M.
- Marshall Wace first reported a position in Intersect ENT, Inc in Q1 2016 and held it in 8 quarters.
- Marshall Wace's Intersect ENT, Inc position peaked at $5.13M in Q1 2017.
- 0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.
Based on Marshall Wace's 13F filing for Q2 2022, filed 15 Aug 2022.